充分的报告对于评估预测预后模型的性能和临床效用至关重要。先前的研究表明，在涉及多变量预后预测模型开发的转化和临床研究中，存在不完整或次优报告的现象，这限制了这些模型的潜在应用。虽然已建立的指南引入的报告模板为统一报告预后研究提供了宝贵的框架，但普遍缺乏合格的遵从，可能是由于在精准医学时代手动报告广泛模型细节所带来的琐碎挑战。在这里，我们提出了ReProMSig（可重复的预后分子标志），这是一个基于网络的综合平台，提供了用于癌症预后的多变量预测模型的开发、验证和应用的分析框架，使用临床病理特征和/或分子特征。ReProMSig平台通过以严格结构化报告文件的形式呈现方法细节和分析结果，支持透明报告，符合指南清单，最大限度地减少了手动输入的需求。生成的报告文件可以与开发的预测模型一起发表，以允许全面的调查和外部验证，以及用于预期病例的在线应用。我们通过分别使用ReProMSig开发了针对II期和III期结直肠癌的预后分子标志，与ReProMSig复现的已发表标志进行了比较，证明了ReProMSig的用途。总之，ReProMSig在更透明、可重复的方式下为癌症预后/预测生物标志物的开发、评估和应用提供了一个集成框架，这将成为医疗保健专业人员和生物医学研究者的有用资源。© 2023作者。由牛津大学出版社出版。保留所有权利。若需获得权限，请发送电子邮件至：journals.permissions@oup.com。

Adequate reporting is essential for evaluating the performance and clinical utility of a prognostic prediction model. Previous studies indicated a prevalence of incomplete or suboptimal reporting in translational and clinical studies involving development of multivariable prediction models for prognosis, which limited the potential applications of these models. While reporting templates introduced by the established guidelines provide an invaluable framework for reporting prognostic studies uniformly, there is a widespread lack of qualified adherence, which may be due to miscellaneous challenges in manual reporting of extensive model details, especially in the era of precision medicine. Here, we present ReProMSig (Reproducible Prognosis Molecular Signature), a web-based integrative platform providing the analysis framework for development, validation and application of a multivariable prediction model for cancer prognosis, using clinicopathological features and/or molecular profiles. ReProMSig platform supports transparent reporting by presenting both methodology details and analysis results in a strictly structured reporting file, following the guideline checklist with minimal manual input needed. The generated reporting file can be published together with a developed prediction model, to allow thorough interrogation and external validation, as well as online application for prospective cases. We demonstrated the utilities of ReProMSig by development of prognostic molecular signatures for stage II and III colorectal cancer respectively, in comparison with a published signature reproduced by ReProMSig. Together, ReProMSig provides an integrated framework for development, evaluation and application of prognostic/predictive biomarkers for cancer in a more transparent and reproducible way, which would be a useful resource for health care professionals and biomedical researchers.© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.